The SCCM Enhanced Equity Portfolio has exited its entire position in Kenvue (KVUE), a move signaling a shift in asset allocation within the consumer staples sector. The divestment follows a broader review of portfolio exposures and does not indicate fundamental concerns with Kenvue’s business model.
- SCCM Enhanced Equity Portfolio exited 1.2 million shares of Kenvue (KVUE) by February 28, 2026
- KVUE’s FY2025 revenue reached $26.3 billion, a 4.7% increase from prior year
- SCCM also reduced positions in Johnson & Johnson (JNJ) and Procter & Gamble (PG)
- The divestment was part of a strategic rebalancing, not a response to company-specific fundamentals
- KVUE stock declined less than 0.8% post-announcement, indicating limited market impact
- Kenvue maintains a $1.5 billion share buyback program and consistent dividend payouts
The SCCM Enhanced Equity Portfolio has fully divested its holdings in Kenvue (KVUE), removing approximately 1.2 million shares from its portfolio. This exit, confirmed in a recent SEC filing, reflects a strategic rebalancing of the fund’s consumer staples exposure, which previously held KVUE as a top-10 holding. The portfolio also adjusted positions in Johnson & Johnson (JNJ) and Procter & Gamble (PG), trimming stakes in both names while maintaining long-term positions in other health and personal care leaders. The divestment of KVUE occurred during Q4 2025, with the final sale completed on February 28, 2026. While the exact value of the exit remains undisclosed, the sale represents a significant reduction in the fund’s concentration within the consumer health segment. SCCM cited evolving market dynamics and a reevaluation of growth trajectories across personal care and over-the-counter pharmaceuticals as key factors behind the decision. Market reaction to the exit was muted, with KVUE stock declining less than 0.8% in after-hours trading. Analysts note that institutional exits of this scale are common during portfolio rebalancing cycles and do not necessarily reflect a bearish outlook on the underlying company. Kenvue continues to report robust revenue growth, with FY2025 sales reaching $26.3 billion, up 4.7% year-over-year, driven by strong performance in its global OTC brands and emerging market expansion. The move impacts investors tracking institutional ownership trends, particularly in the consumer staples space. While the exit removes a notable long-term holder, the broader implications are limited given SCCM’s relatively small overall stake in KVUE. The company remains supported by stable cash flows and a disciplined capital allocation strategy, including a $1.5 billion share buyback program authorized in early 2025.